References
- Roberts DT, Taylor WD, Boyle J. Guidelines for treatment of onychomycosis. Br J Dermatol. 2003;148:402–410.
- Seebacher C, Bouchara JP, Mignon B. Updates on the epidemiology of dermatophyte infections. Mycopathologia. 2008;166:335–352.
- Drake L, Babel D, Steward DM, Rich P, Ling MR, Breneman D, Once-weely fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. J Am Acad Dermatol. 1998;38:S87–S94.
- Havu V, Heikkila H, Kuokkanen K, Nuutinen M, Rantanen T, Saari S, A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil®) with fluconazole (Diflucan®) in the treatment of onychomycosis. Br J Dermatol. 2000;142:97–102.
- Ling MR, Swinyer LJ, Jarratt MT, Falo L, Monroe EW, Tharp M, Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998;38(6 Pt 2):S95–102.
- Montero-Gei F, Robles-Soto ME, Schlager H. Fluconazole in the treatment of severe onychomycosis. Int J Dermatol. 1996;35:587–588.
- Scher RK, Breneman D, Rich P, Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol. 1998;38(6 Pt 2):S77–S86.
- Gupta AK, Gregure-Nova T. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the Treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology. 2001;202:235–238.
- Dourmishev L, Bardarov E, Dourmishev A, Kantardjiev T, Zisova L, Kuseva V, Fluconazole in the treatment of onychomycosis. Acta Med Bulgarica. 2006;33:60–69.
- Smith SW, Sealy DP, Schneider E, Lackland D. An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis. South Med J. 1995;88:1217–1220.
- European medicines agency (EMA). Questions and answers on Diflucan and associated names (fluconazole, 50, 100, 150 and 200 mg capsules, oral solution 5 mg/ml, powder for oral suspension 10 mg/ml or 40 mg/ml, solution for infusion 2 mg/ml), Outcome of a procedure under Article 30 of Directive 2001/83/EC. 2011. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Diflucan_30/WC500108008.pdf. Accessed on January 31 2012.
- Shear N, Drae L, Gupta AK, Lambert J, Yaniv R. The implications and management of drug interactions with itraconazole, fluconazole and terbinafine. Dermatology. 2000;201:196–203.
- Gupta AK, Kopstein B, Shear NH. Hypersensitivity reaction to terbinafine. J Am Acad Dermatol. 1997;36:1018–1019.
- Martinez-Rossi NM, Peres NTA, Rossi A. Antifungal resistance mechanisms in dermatophytes. Mycopathologia. 2008;166:369–383.
- Grant SM, Clissord SP. Fluconazole a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs. 1990;39:877–916.
- Laufen H, Zimmermann T, Yeates RA, Schumacher T, Wildfeuer A. The uptake of fluconazole in finger and toe nails. Int J Clin Pharmacol Ther. 1999;37:352–360.
- Chang CH, Young-Xu Y, Kurth T, Orav JE, Chan AK. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Am J Med. 2007;120:791–798.
- Kruk ME, Schwalbe N. The relation between intermittent dosing and adherence: preliminary insights. Clin Ther. 2006;28:1989–1995.
- Brown SJ. Efficacy of fluconazole for the treatment of onychomycosis. Annals Pharmacother. 2009;43:1684–1690.
- Arca E, Tastan HB, Akar A, Kurumlu Z, Gur AR. An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. J Dermatolog Treat. 2002;13:3–9.
- Elewski BE. Mechanisms of action of systemic antifungal agents. J Am Acad Dermatol. 1993;28:S28–S34.
- Debruyne D, Coquerel A. Pharmacokinetics of antifungal agents in onychomycoses. Clin Pharmacoinet. 2001;40:441–472.